THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Rajagopal Ramesh to Lung Neoplasms

This is a "connection" page, showing publications Rajagopal Ramesh has written about Lung Neoplasms.
Connection Strength

9.847
  1. Identification of SMARCAL1 as a molecular target for small cell lung cancer treatment. Cancer Lett. 2024 Jun 28; 592:216932.
    View in: PubMed
    Score: 0.706
  2. Drug delivery approaches for HuR-targeted therapy for lung cancer. Adv Drug Deliv Rev. 2022 01; 180:114068.
    View in: PubMed
    Score: 0.595
  3. Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer. Adv Drug Deliv Rev. 2021 11; 178:113918.
    View in: PubMed
    Score: 0.583
  4. Tumor-Targeted Dendrimer Nanoparticles for Combinatorial Delivery of siRNA and Chemotherapy for Cancer Treatment. Methods Mol Biol. 2020; 2059:167-189.
    View in: PubMed
    Score: 0.522
  5. Combinatorial Nanoparticle Delivery of siRNA and Antineoplastics for Lung Cancer Treatment. Methods Mol Biol. 2019; 1974:265-290.
    View in: PubMed
    Score: 0.487
  6. Exosomes as Theranostics for Lung Cancer. Adv Cancer Res. 2018; 139:1-33.
    View in: PubMed
    Score: 0.454
  7. Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy. Sci Rep. 2017 11 07; 7(1):14674.
    View in: PubMed
    Score: 0.449
  8. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther. 2017 08; 16(8):1470-1486.
    View in: PubMed
    Score: 0.436
  9. Polymeric Nanoparticle-Mediated Gene Delivery for Lung Cancer Treatment. Top Curr Chem (Cham). 2017 Apr; 375(2):35.
    View in: PubMed
    Score: 0.429
  10. Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells. Sci Rep. 2016 12 12; 6:38541.
    View in: PubMed
    Score: 0.422
  11. IL-24 modulates the high mobility group (HMG) A1/miR222 /AKT signaling in lung cancer cells. Oncotarget. 2016 Oct 25; 7(43):70247-70263.
    View in: PubMed
    Score: 0.418
  12. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnology. 2016 Jun 21; 14(1):47.
    View in: PubMed
    Score: 0.408
  13. Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy. Int J Nanomedicine. 2015; 10:6773-88.
    View in: PubMed
    Score: 0.391
  14. HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer. Cancer Gene Ther. 2015 Dec; 22(12):581-90.
    View in: PubMed
    Score: 0.390
  15. Phosphorylation of interleukin (IL)-24 is required for mediating its anti-cancer activity. Oncotarget. 2015 Jun 30; 6(18):16271-86.
    View in: PubMed
    Score: 0.382
  16. EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage. Int J Nanomedicine. 2014; 9:3825-39.
    View in: PubMed
    Score: 0.359
  17. Inhibition of nuclear factor-kappaB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation. Mol Cancer Ther. 2007 Apr; 6(4):1440-9.
    View in: PubMed
    Score: 0.215
  18. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther. 2007 Feb; 15(2):287-94.
    View in: PubMed
    Score: 0.213
  19. Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb; 4(2):291-304.
    View in: PubMed
    Score: 0.186
  20. Nanoparticle based systemic gene therapy for lung cancer: molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response. Technol Cancer Res Treat. 2004 Dec; 3(6):647-57.
    View in: PubMed
    Score: 0.183
  21. Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery. DNA Cell Biol. 2004 Dec; 23(12):850-7.
    View in: PubMed
    Score: 0.183
  22. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther. 2004 Nov; 11(11):733-9.
    View in: PubMed
    Score: 0.182
  23. Ectopic production of MDA-7/IL-24 inhibits invasion and migration of human lung cancer cells. Mol Ther. 2004 Apr; 9(4):510-8.
    View in: PubMed
    Score: 0.175
  24. Increased uptake of liposomal-DNA complexes by lung metastases following intravenous administration. Mol Ther. 2003 Mar; 7(3):409-18.
    View in: PubMed
    Score: 0.162
  25. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene. 2002 Jul 04; 21(29):4558-66.
    View in: PubMed
    Score: 0.155
  26. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine. 2018 02; 14(2):373-384.
    View in: PubMed
    Score: 0.113
  27. IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis. PLoS One. 2015; 10(3):e0122439.
    View in: PubMed
    Score: 0.094
  28. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012; 7(4):e34833.
    View in: PubMed
    Score: 0.077
  29. Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 2009 Dec 01; 15(23):7299-308.
    View in: PubMed
    Score: 0.065
  30. Cancer targeting using tumor suppressor genes. Front Biosci. 2008 Jan 01; 13:1959-67.
    View in: PubMed
    Score: 0.057
  31. Nanoparticle-mediated gene delivery to the lung. Methods Mol Biol. 2008; 433:301-31.
    View in: PubMed
    Score: 0.057
  32. Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation. Mol Ther. 2004 Jun; 9(6):818-28.
    View in: PubMed
    Score: 0.044
  33. Persistent transgene expression following intravenous administration of a liposomal complex: role of interleukin-10-mediated immune suppression. Mol Ther. 2004 Mar; 9(3):318-27.
    View in: PubMed
    Score: 0.044
  34. The tumor suppressor activity of MDA-7/IL-24 is mediated by intracellular protein expression in NSCLC cells. Mol Ther. 2004 Mar; 9(3):355-67.
    View in: PubMed
    Score: 0.044
  35. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. Mol Ther. 2003 Aug; 8(2):207-19.
    View in: PubMed
    Score: 0.042
  36. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther. 2002 Nov; 1(13):1201-9.
    View in: PubMed
    Score: 0.040
  37. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2002 Sep; 8(9):2963-9.
    View in: PubMed
    Score: 0.039
  38. HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Sci Rep. 2017 08 30; 7(1):9694.
    View in: PubMed
    Score: 0.028
  39. Targeting single-walled carbon nanotubes for the treatment of breast cancer using photothermal therapy. Nanotechnology. 2013 Sep 20; 24(37):375104.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES